Claritev appointed Ben Letham as a Class I director and added him to its Risk Committee effective September 14, 2026, filling a vacancy on the board. The appointment gives investors a stated board-level focus on artificial intelligence, data analysis and innovation as Claritev expands AI across its healthcare solutions.

Key Highlights

  • Ben Letham’s appointment became effective September 14, 2026.
  • Letham will receive compensation under Claritev’s non-employee director policy.
  • Claritev issued a press release announcing the appointment on September 15, 2026.

Claritev Corp (NYSE: CTEV) appointed Ben Letham as a Class I director effective September 14, 2026, adding him to the board’s Risk Committee.

Class I Seat and Risk Committee Assignment

Letham will be compensated under Claritev’s policy for non-employee directors and will sign the company’s standard indemnification agreement. Claritev said Letham has no family relationship with any director or executive officer and no direct or indirect material interest in a transaction requiring disclosure under applicable securities rules. The company issued a press release about the appointment on September 15, 2026. Letham currently serves as a research scientist and has worked on AI, optimization systems, digital experimentation and applied data analysis.

AI Expertise Added to Board Strategy

Claritev said Letham’s experience is intended to support its long-term strategic objectives and innovation initiatives. The company said it is deploying more AI across its solutions to help clients address complex Business challenges. Its platform uses analytics and AI to support affordability, price transparency, network design and benefits design.